EX-FILING FEES 4 d349919dexfilingfees.htm EX-FILING FEES EX-FILING FEES

Exhibit 107

Calculation of Filing Fee Tables

Form S-3

(Form Type)

Mirum Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

 

                         
     Security
Type		   Security
Class
Title		   Fee
Calculation
or Carry
Forward
Rule		   Amount
Registered(1)		   Proposed
Maximum
Offering
Price Per
Share		   Maximum
Aggregate
Offering
Price		   Fee
Rate		   Amount of
Registration
Fee		  

Carry
Forward

Form
Type

  

Carry

Forward

File

Number

   Carry
Forward
Initial
Effective
Date		   Filing Fee
Previously
Paid In
Connection
with Unsold
Securities to
be Carried
Forward
 
Newly Registered Securities
                         

Fees to be

Paid

   Equity   Common Stock, par value $0.0001 per share   Other   609,305(2)   $23.66(3)   $14,416,156.30   $0.0000927   $1,337   —   —   —   —
                         

Fees to be

Paid

   Equity   Common Stock, par value $0.0001 per share   Other   32,494(4)   $23.66(3)   $768,808.04   $0.0000927   $72   —   —   —   —
                         

Fees to be

Paid

   Equity   Common Stock, par value $0.0001 per share   Other   199,993(5)   $23.66(3)   $4,731,834.38   $0.0000927   $439          
                         

Fees

Previously

Paid

   —   —   —   —   —   —   —   —   —   —   —   —
 
Carry Forward Securities
                         

Carry

Forward

Securities

   —   —   —   —   —   —   —   —   —   —   —   —
                   
    Total Offering Amounts      $19,916,798.72     $1,848          
                   
    Total Fees Previously Paid          —          
                   
    Total Fee Offsets          —          
                   
    Net Fee Due                —                

 

(1)

Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers any additional number of shares of common stock issuable upon stock splits, stock dividends, or other distribution, recapitalization or similar events with respect to the shares of common stock being registered pursuant to this registration statement.

(2)

Consists of 609,305 shares of the Registrant’s common stock held by the selling stockholders named in the prospectus that forms a part of this registration statement.

(3)

Estimated solely for the purposes of calculating the registration fee pursuant to Rule 457(c) under the Securities Act, based on the average of the high and low price per share of the Registrant’s common stock as reported by the Nasdaq Global Market on May 19, 2022.

(4)

Consists of 32,494 shares of the Registrant’s common stock issuable to the selling stockholders named in the prospectus that forms a part of this registration statement that are held back to satisfy any potential indemnification and other obligations of the prior equityholders of the Registrant’s subsidiary, Satiogen Pharmaceuticals, Inc., a Delaware corporation.

(5)

Consists of 199,993 shares of the Registrant’s common stock issuable as merger consideration to the selling stockholders named in the prospectus that forms a part of this registration statement upon the Registrant’s achievement of a certain milestone.